Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
World Neurosurg ; 155: e142-e149, 2021 11.
Article de Anglais | MEDLINE | ID: mdl-34400327

RÉSUMÉ

BACKGROUND: The coronavirus disease identified in 2019 (COVID-19) pandemic changed neurosurgery protocols to provide ongoing care for patients while ensuring the safety of health care workers. In Brazil, the rapid spread of the disease led to new challenges in the health system. Neurooncology practice was one of the most affected by the pandemic due to restricted elective procedures and new triage protocols. We aim to characterize the impact of the pandemic on neurosurgery in Brazil. METHODS: We analyzed 112 different types of neurosurgical procedures, with special detail in 11 neurooncology procedures, listed in the Brazilian Hospital Information System records in the DATASUS database between February and July 2019 and the same period in 2020. Linear regression and paired t-test analyses were performed and considered statistically significant at P < 0.05. RESULTS: There was an overall decrease of 21.5% (28,858 cases) in all neurosurgical procedures, impacting patients needing elective procedures (-42.46%) more than emergency surgery (-5.93%). Neurooncology procedures decreased by 14.89%. Nonetheless, the mortality rate during hospitalization increased by 21.26%. Linear regression analysis in hospitalizations (Slope = 0.9912 ± 0.07431; CI [95%] = 0.8231-1.159) and total cost (Slope = 1.03 ± 0.03501; CI [95%] = 0.9511-1.109) in the 11 different types of neurooncology procedures showed a P < 0.0001. The mean cost per type of procedure showed an 11.59% increase (P = 0.0172) between 2019 and 2020. CONCLUSIONS: The COVID-19 pandemic has increased mortality, decreased hospitalizations, and therefore decreased overall costs, despite increased costs per procedure for a variety of neurosurgical procedures. Our study serves as a stark example of the effect of the pandemic on neurosurgical care in settings of limited resources and access to care.


Sujet(s)
COVID-19/épidémiologie , Prestations des soins de santé/tendances , Pays en voie de développement , Systèmes d'information hospitaliers/tendances , Procédures de neurochirurgie/tendances , Brésil/épidémiologie , COVID-19/économie , COVID-19/prévention et contrôle , Prestations des soins de santé/économie , Pays en voie de développement/économie , Personnel de santé/économie , Personnel de santé/tendances , Systèmes d'information hospitaliers/économie , Humains , Procédures de neurochirurgie/économie , Équipement de protection individuelle/économie , Équipement de protection individuelle/tendances
2.
CNS Neurol Disord Drug Targets ; 18(1): 52-62, 2019.
Article de Anglais | MEDLINE | ID: mdl-30394222

RÉSUMÉ

BACKGROUND: The chronic phase of Spinal Cord (SC) injury is characterized by the presence of a hostile microenvironment that causes low activity and a progressive decline in neurological function; this phase is non-compatible with regeneration. Several treatment strategies have been investigated in chronic SC injury with no satisfactory results. OBJECTIVE- In this proof-of-concept study, we designed a combination therapy (Comb Tx) consisting of surgical glial scar removal plus scar inhibition, accompanied with implantation of mesenchymal stem cells (MSC), and immunization with neural-derived peptides (INDP). METHODS: This study was divided into three subsets, all in which Sprague Dawley rats were subjected to a complete SC transection. Sixty days after injury, animals were randomly allocated into two groups for therapeutic intervention: control group and animals receiving the Comb-Tx. Sixty-three days after treatment we carried out experiments analyzing motor recovery, presence of somatosensory evoked potentials, neural regeneration-related genes, and histological evaluation of serotoninergic fibers. RESULTS: Comb-Tx induced a significant locomotor and electrophysiological recovery. An increase in the expression of regeneration-associated genes and the percentage of 5-HT+ fibers was noted at the caudal stump of the SC of animals receiving the Comb-Tx. There was a significant correlation of locomotor recovery with positive electrophysiological activity, expression of GAP43, and percentage of 5-HT+ fibers. CONCLUSION: Comb-Tx promotes motor and electrophysiological recovery in the chronic phase of SC injury subsequent to a complete transection. Likewise, it is capable of inducing the permissive microenvironment to promote axonal regeneration.


Sujet(s)
Cicatrice/chirurgie , Association thérapeutique/méthodes , Transplantation de cellules souches mésenchymateuses , Récupération fonctionnelle/effets des médicaments et des substances chimiques , Récupération fonctionnelle/immunologie , Traumatismes de la moelle épinière , 2,2'-Bipyridine/usage thérapeutique , Animaux , Potentiels évoqués/physiologie , Femelle , Adjuvant Freund/usage thérapeutique , Expression des gènes/effets des médicaments et des substances chimiques , Activité motrice/effets des médicaments et des substances chimiques , Régénération nerveuse/effets des médicaments et des substances chimiques , Rats , Traumatismes de la moelle épinière/traitement médicamenteux , Traumatismes de la moelle épinière/physiopathologie , Traumatismes de la moelle épinière/chirurgie , Traumatismes de la moelle épinière/thérapie , Tryptophane/analogues et dérivés , Tryptophane/usage thérapeutique
3.
BMC Neurosci ; 18(1): 7, 2017 01 05.
Article de Anglais | MEDLINE | ID: mdl-28056790

RÉSUMÉ

BACKGROUND: Immunization with neural derived peptides (INDP) as well as scar removal-separately-have shown to induce morphological and functional improvement after spinal cord injury (SCI). In the present study, we compared the effect of INDP alone versus INDP with scar removal on motor recovery, regeneration-associated and cytokine gene expression, and axonal regeneration after chronic SCI. Scar removal was conducted through a single incision with a double-bladed scalpel along the stump, and scar renewal was halted by adding α,α'-dipyridyl. RESULTS: During the chronic injury stage, two experiments were undertaken. The first experiment was aimed at testing the therapeutic effect of INDP combined with scar removal. Sixty days after therapeutic intervention, the expression of genes encoding for TNFα, IFNγ, IL4, TGFß, BDNF, IGF1, and GAP43 was evaluated at the site of injury. Tyrosine hydroxylase and 5-hydroxytryptamine positive fibers were also studied. Locomotor evaluations showed a significant recovery in the group treated with scar removal + INDP. Moreover; this group presented a significant increase in IL4, TGFß, BDNF, IGF1, and GAP43 expression, but a decrease of TNFα and IFNγ. Also, the spinal cord of animals receiving both treatments presented a significant increase of serotonergic and catecholaminergic fibers as compared to other the groups. The second experiment compared the results of the combined approach versus INDP alone. Rats receiving INDP likewise showed improved motor recovery, although on a lesser scale than those who received the combined treatment. An increase in inflammation and regeneration-associated gene expression, as well as in the percentage of serotonergic and catecholaminergic fibers was observed in INDP-treated rats to a lesser degree than those in the combined therapy group. CONCLUSIONS: These findings suggest that INDP, both alone and in combination with scar removal, could modify the non-permissive microenvironment prevailing at the chronic phase of SCI, providing the opportunity of improving motor recovery.


Sujet(s)
Cicatrice/métabolisme , Locomotion/effets des médicaments et des substances chimiques , Neuropeptides/administration et posologie , Traumatismes de la moelle épinière/immunologie , Traumatismes de la moelle épinière/métabolisme , Vaccination , Animaux , Facteur neurotrophique dérivé du cerveau/métabolisme , Maladie chronique , Cytokines/métabolisme , Modèles animaux de maladie humaine , Femelle , Protéine GAP-43/métabolisme , Facteur de croissance IGF-I/métabolisme , Interféron gamma/métabolisme , Interleukine-4/métabolisme , Neuropeptides/usage thérapeutique , Rats , Rat Sprague-Dawley , Récupération fonctionnelle , Traumatismes de la moelle épinière/traitement médicamenteux , Régénération de la moelle épinière/génétique , Facteur de croissance transformant bêta/métabolisme , Facteur de nécrose tumorale alpha/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE